These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2511218)

  • 1. Resolution of enantiomers of the antiarrhythmic drug encainide and its major metabolites by chiral derivatization and high-performance liquid chromatography.
    Prakash C; Jajoo HK; Blair IA; Mayol RF
    J Chromatogr; 1989 Sep; 493(2):325-35. PubMed ID: 2511218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of encainide and its metabolites by high-performance liquid chromatography.
    Selinger K; Crawhall JC
    J Pharm Biomed Anal; 1989; 7(3):355-9. PubMed ID: 2518704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enantioselective metabolism of encainide by rat liver microsomes.
    Jajoo HK; Prakash C; Mayol RF; Blair IA
    Biochem Pharmacol; 1990 Aug; 40(4):893-5. PubMed ID: 2117457
    [No Abstract]   [Full Text] [Related]  

  • 4. Structural characterization of urinary metabolites of the antiarrhythmic drug encainide in human subjects.
    Jajoo HK; Mayol RF; LaBudde JA; Blair IA
    Drug Metab Dispos; 1990; 18(1):28-35. PubMed ID: 1970774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of encainide and metabolites in plasma and urine by high-performance liquid chromatography.
    Bartek MJ; Mayol RF; Boarman MP; Gammans RE; Gallo DG
    Ther Drug Monit; 1988; 10(4):446-52. PubMed ID: 3144068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved high-performance liquid chromatographic assay for encainide and its metabolites in human body fluids.
    Turgeon J; Funck-Brentano C; Gray HT; Roden DM
    J Chromatogr; 1989 May; 490(1):165-74. PubMed ID: 2503530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assay of tocainide enantiomers in plasma by solid-phase extraction and indirect chiral high-performance liquid chromatography after derivatization with (-)-menthyl chloroformate.
    Christensen EB; Hansen SH; Rasmussen SN
    J Chromatogr B Biomed Appl; 1995 Aug; 670(2):243-9. PubMed ID: 8548014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative antiarrhythmic actions of encainide and its major metabolites.
    Gomoll AW; Byrne JE; Mayol RF
    Arch Int Pharmacodyn Ther; 1986 Jun; 281(2):277-97. PubMed ID: 3092755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high-performance liquid chromatographic method for the determination of encainide and its major metabolites in urine and serum using solid-phase extraction.
    Kazierad DJ; Hoon TJ; Bottorff MB
    Ther Drug Monit; 1989; 11(3):327-31. PubMed ID: 2499083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Encainide and metabolites analysis in serum or plasma using a reversed-phase high-performance liquid chromatographic technique.
    Dasgupta A; Rosenzweig IB; Turgeon J; Raisys VA
    J Chromatogr; 1990 Mar; 526(1):260-5. PubMed ID: 2111331
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical importance of metabolites of antiarrhythmic drugs.
    Kates RE; Woosley RL; Harrison DC
    Am J Cardiol; 1984 Jan; 53(1):248-51. PubMed ID: 6419577
    [No Abstract]   [Full Text] [Related]  

  • 12. Chiral purity test of metoprolol enantiomer after derivatization with (-)-menthyl chloroformate by reversed-phase high performance liquid chromatography.
    Kim KH; Choi PW; Hong SP; Kim HJ
    Arch Pharm Res; 1999 Dec; 22(6):614-8. PubMed ID: 10615868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidative metabolism of encainide: polymorphism, pharmacokinetics and clinical considerations.
    McAllister CB; Wolfenden HT; Aslanian WS; Woosley RL; Wilkinson GR
    Xenobiotica; 1986 May; 16(5):483-90. PubMed ID: 3090789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resolution and absolute configuration of 7,12-dimethylbenz[a]anthracene 5,6-epoxide enantiomers.
    Mushtaq M; Weems HB; Yang SK
    Biochem Biophys Res Commun; 1984 Dec; 125(2):539-45. PubMed ID: 6440560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial uptake of encainide and its two major metabolites, O-demethyl encainide and 3-methoxy-O-demethyl encainide, in the dog.
    Latini R; Gillis AM; Kates RE
    J Cardiovasc Pharmacol; 1984; 6(4):663-7. PubMed ID: 6206322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and metabolism of encainide.
    Jaillon P
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():561-5. PubMed ID: 2125833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resolution and isolation of enantiomers of (±)-isoxsuprine using thin silica gel layers impregnated with L-glutamic acid, comparison of separation of its diastereomers prepared with chiral derivatizing reagents having L-amino acids as chiral auxiliaries.
    Bhushan R; Nagar H
    Biomed Chromatogr; 2015 Mar; 29(3):357-65. PubMed ID: 25044026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiarrhythmic activity of the O-demethyl metabolite of encainide.
    Roden DM; Duff HJ; Altenbern D; Woosley RL
    J Pharmacol Exp Ther; 1982 Jun; 221(3):552-7. PubMed ID: 6806461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolite cumulation during long-term oral encainide administration.
    Kates RE; Harrison DC; Winkle RA
    Clin Pharmacol Ther; 1982 Apr; 31(4):427-32. PubMed ID: 6800679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resolution of epoxide enantiomers of polycyclic aromatic hydrocarbons by chiral stationary-phase high-performance liquid chromatography.
    Weems HB; Mushtaq M; Yang SK
    Anal Biochem; 1985 Aug; 148(2):328-38. PubMed ID: 4061813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.